拉米夫定联合阿德福韦与恩替卡韦单药治疗在慢性乙肝的疗效分析(2)
第1页 |
参见附件。
参考文献
[1]黄平,杨永峰,钟华平.恩替卡韦和拉米夫定治疗慢性重症肝炎的I临床观察[J].肝脏,2008,13(1):85.
[2]霍丽亚.恩替卡韦治疗慢性重型肝炎疗效观察[J].新乡医学院学报,2008,29(5):484.
[3]李芬,陶晨,杜建霞.恩替卡韦治疗慢性乙型重型肝炎的近期疗效观察[J].实用肝脏病杂志,2008,11(6):383.
[4]陈春,陈小平,伍思国.恩替卡韦治疗慢性重度乙型肝炎60例临床观察[J].广东医学院学报,2009,27(3):296-297.
[5]LEINONNEN E,HURT.CAMEJO E WIKLUND O.et al Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes[J].Atherosclemsis,2003,166(2):387-394.
[6]Vozarova B,W eyer C, Lindsay RS,et a1. High white blood Cell count is associated with a worsening of insulin sensitivityand predicts the development of type 2 diabetes. Diabetes,2002,51:455-461.
[7]Wolf M,Sauk J,Shah A,et a1.Inflammation and glucose intolerance: a prospective study of gestational diabetesmellitus[J].Diabetes Care,2004,27(1):21-27.
[8] Qiu C,Sorensen TK,Luthy DA,et a1.A prospective study of materna1 serum C-reactive protein (CRP) concentrations and risk of gestational diabetes mellitus.Paediatr Perinat Epidemio1,2004,18:377-384
您现在查看是摘要介绍页,详见PDF附件(2314kb)。